Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Overview
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Companies Involved in Therapeutics Development
Bristol-Myers Squibb Co
Curadim Pharma Co Ltd
Horizon Therapeutics PLC
Novo Nordisk AS
Ono Pharmaceutical Co Ltd
RxBio Inc
Takeda Pharmaceutical Co Ltd
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Drug Profiles
BMS-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986278 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CP-2090 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EPGN-696 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HZN-825 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-7300243 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rx-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize LPA1 for Pulmory Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-615 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Dormant Products
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Discontinued Products
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Product Development Milestones
Featured News & Press Releases
Sep 28, 2011: RxBio Receives $15m BARDA Contract For Development Of Rx100 To Protect Against Radiation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Bristol-Myers Squibb Co, H1 2020
Pipeline by Curadim Pharma Co Ltd, H1 2020
Pipeline by Horizon Therapeutics PLC, H1 2020
Pipeline by Novo Nordisk AS, H1 2020
Pipeline by Ono Pharmaceutical Co Ltd, H1 2020
Pipeline by RxBio Inc, H1 2020
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Discontinued Products, H1 2020